Adagrasib INN 200 mg (Krazati)

Product Overview: Adagrasib (INN 200 mg) is a targeted cancer therapy used to treat certain types of non-small cell lung cancer (NSCLC) and other cancers harboring KRAS G12C mutations. Adagrasib works by specifically inhibiting the KRAS G12C protein, which plays a key role in the growth and survival of cancer cells.

Key Benefits:

• Targeted treatment for cancers with KRAS G12C mutation.
• Helps in slowing tumor growth or shrinking tumors.
• Oral medication, making it convenient for patients.

Indications: Adagrasib is typically prescribed for adult patients with advanced or metastatic KRAS G12C-mutant NSCLC who have already received prior treatment with chemotherapy.

Dosage of Adagrasib INN 200 mg (Krazati)

• The recommended dose is 200 mg taken orally twice daily, with or without food.
• Always follow your healthcare provider’s instructions regarding the dosage and usage.

Precautions:

• Ensure to inform your healthcare provider of any medical conditions or other medications you’re taking.
• Common side effects may include diarrhea, nausea, fatigue, liver enzyme elevation, and others.
• Regular monitoring by a healthcare professional is required to manage side effects.

Packaging:

• Adagrasib 200 mg tablets are provided in a [insert packaging type] for convenience and safety.

Important Notes:

• This medication should only be used under the supervision of a licensed healthcare provider.
• Ensure to store this product as per the instructions on the packaging (typically in a cool, dry place away from direct sunlight).